Differences between cancers may originate from variable frequencies of CD161 expressing CD4+ and CD8+ TILs, as observed between glioblastomas, NSCLC and OPSCC or they may originate from heterogeneity of the TME and antitumor immune responses. This evidence concerns the gene CD4 and non-small cell lung carcinoma.